ArriVent BioPharma, Inc. (AVBP) Ownership
AVBP ownership summary
as of October 18, 2026- Institutions
- 100.4% of shares outstanding
- Insiders
- 1.54% of shares outstanding
- Shares outstanding
- 49.3M
- Float
- 29.6M shares available to trade
- Short interest
- 18.18% 8.5M shares short
- Days to cover
- 13.52 short interest down 3.6% vs prior month
- Institutions 100.42%
- Insiders 1.54%
AVBP top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.16% | 4.5M | $75.2M | +114,448 (+2.6%) | June 30, 2026 |
| 2 | Hillhouse Capital Advisors, Ltd. | 7.97% | 3.9M | $65.5M | — | June 30, 2026 |
| 3 | BlackRock Inc | 6.59% | 3.3M | $54.2M | +720,095 (+28.5%) | June 30, 2026 |
| 4 | Orbimed Advisors LLC | 6.14% | 3.0M | $50.4M | — | June 30, 2026 |
| 5 | FMR Inc | 5.64% | 2.8M | $46.3M | −237,173 (−7.9%) | June 30, 2026 |
| 6 | Octagon Capital Advisors LP | 4.00% | 2.0M | $32.8M | — | June 30, 2026 |
| 7 | Vanguard Capital Management, LLC | 3.60% | 1.8M | $29.6M | +245,980 (+16.1%) | June 30, 2026 |
| 8 | Sofinnova Ventures | 3.44% | 1.7M | $28.3M | — | June 30, 2026 |
| 9 | State Street Corp | 3.43% | 1.7M | $28.2M | +271,571 (+19.1%) | June 30, 2026 |
| 10 | Vivo Capital, LLC | 3.41% | 1.7M | $28.0M | +796,181 (+89.9%) | June 30, 2026 |
| 11 | Novo A/S | 3.04% | 1.5M | $25.0M | −442,142 (−22.8%) | June 30, 2026 |
| 12 | General Catalyst Group Management, LLC | 3.03% | 1.5M | $24.9M | — | June 30, 2026 |
| 13 | Logos Global Management LP | 2.03% | 1.0M | $16.7M | +650,000 (+185.7%) | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 1.97% | 973K | $16.2M | +168,974 (+21.0%) | June 30, 2026 |
| 15 | D. E. Shaw & Co LP | 1.77% | 872K | $14.5M | +503,216 (+136.4%) | June 30, 2026 |
| 16 | The Goldman Sachs Group Inc | 1.73% | 854K | $14.2M | +296 (+0.0%) | June 30, 2026 |
| 17 | HSG Holding Ltd | 1.35% | 663K | $11.1M | — | June 30, 2026 |
| 18 | Point72 Asset Management, L.P. | 1.15% | 567K | $9.4M | −181,399 (−24.2%) | June 30, 2026 |
| 19 | Millennium Management LLC | 0.89% | 439K | $7.3M | +12,741 (+3.0%) | June 30, 2026 |
| 20 | UBS Group AG | 0.89% | 439K | $7.3M | −47,669 (−9.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 10 holders added 3.5M shares and 4 cut 908K.
AVBP top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | HBM Healthcare Investments AG Ord | 5.17% | 2.5M | $42.5M | — | June 30, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 2.72% | 1.3M | $22.3M | — | August 31, 2026 |
| 3 | Fidelity Select Biotechnology | 2.68% | 1.3M | $22.0M | −31,600 (−2.3%) | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 1.99% | 981K | $16.3M | −11,328 (−1.1%) | September 30, 2026 |
| 5 | State Street® SPDR® S&P® Biotech ETF | 1.88% | 925K | $15.4M | −17,650 (−1.9%) | September 30, 2026 |
| 6 | Fidelity Small Cap Index | 0.84% | 415K | $6.9M | +3,256 (+0.8%) | July 31, 2026 |
| 7 | iShares Russell 2000 Growth ETF | 0.72% | 353K | $5.9M | −447 (−0.1%) | September 30, 2026 |
| 8 | Fidelity Growth Company Fund | 0.66% | 324K | $5.4M | — | August 31, 2026 |
| 9 | Fidelity Small Cap Growth | 0.61% | 299K | $5.0M | — | July 31, 2026 |
| 10 | iShares Biotechnology ETF | 0.55% | 270K | $4.5M | −2,048 (−0.8%) | September 30, 2026 |
| 11 | Schwab US Small-Cap ETF™ | 0.45% | 220K | $3.7M | +144 (+0.1%) | September 30, 2026 |
| 12 | Vanguard Russell 2000 ETF | 0.44% | 218K | $3.6M | +5,166 (+2.4%) | August 31, 2026 |
| 13 | MEDICAL BioHealth EUR Acc | 0.38% | 189K | $3.2M | +94,051 (+98.8%) | August 31, 2026 |
| 14 | Fidelity Extended Market Index | 0.35% | 171K | $2.9M | +475 (+0.3%) | August 31, 2026 |
| 15 | Fidelity Small Cap Growth K6 | 0.30% | 149K | $2.5M | — | July 31, 2026 |
| 16 | Fidelity Enhanced Small Cap Core ETF | 0.29% | 144K | $2.4M | +300 (+0.2%) | September 30, 2026 |
| 17 | iShares Micro-Cap ETF | 0.24% | 120K | $2.0M | −825 (−0.7%) | September 30, 2026 |
| 18 | E Fund Global Medi Inds Allc QDII CNY A | 0.21% | 106K | $1.8M | +105,890 (0.0%) | June 30, 2026 |
| 19 | Schwab Small Cap Index | 0.19% | 92K | $1.5M | — | August 31, 2026 |
| 20 | Fidelity Growth Company K6 | 0.18% | 91K | $1.5M | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
AVBP insider transactions
latest 2| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-30 | Hillhouse Investment Managemen | Buy | $18.00 | 555,555 | $10.0M |
| 2024-01-30 | Orbimed Advisors Llc | Buy | $18.00 | 444,444 | $8.0M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
AVBP shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns AVBP
Institutional investors own 100.4% of ArriVent BioPharma's shares and insiders 1.54%. The largest holder is Suvretta Capital Management, LLC with 9.16% of the shares (4.5M), as of June 30, 2026. Among the top 20 institutions, 10 added shares and 4 reduced their stake in the latest filings. Short interest is 18.18% of the float, or 13.52 days of average trading volume. The share count rose 3,746.3% since 2021.
Related: AVBP analyst forecast, AVBP key metrics. See the AVBP stock overview for the latest quote and news.
AVBP ownership FAQ
Who owns the most ArriVent BioPharma stock?
The largest shareholders of ArriVent BioPharma are Suvretta Capital Management, LLC (9.16%), Hillhouse Capital Advisors, Ltd. (7.97%), BlackRock Inc (6.59%), Orbimed Advisors LLC (6.14%), FMR Inc (5.64%).
What percentage of ArriVent BioPharma is owned by institutions?
Institutions hold 100.4% of ArriVent BioPharma's shares outstanding; insiders hold 1.54%.
Which funds own ArriVent BioPharma?
The largest fund holders of ArriVent BioPharma are HBM Healthcare Investments AG Ord (5.17%), Vanguard MStar Total Stk Mkt Idx Invest (2.72%), Fidelity Select Biotechnology (2.68%), iShares Russell 2000 ETF (1.99%), State Street® SPDR® S&P® Biotech ETF (1.88%).
What is ArriVent BioPharma's short interest?
8.5M shares of ArriVent BioPharma were sold short, 18.18% of the float; at the average daily volume it would take 13.52 days to cover.
Are insiders buying or selling ArriVent BioPharma?
Of the latest 2 reported insider transactions in ArriVent BioPharma (since January 30, 2024), 2 were purchases and 0 were sales.
How many shares of ArriVent BioPharma are outstanding?
ArriVent BioPharma has 49.3M shares outstanding, of which 29.6M are in the public float.